Valuation: Atea Pharmaceuticals, Inc.

Market Cap 411M 367M 342M 311M 586M 39.63B 590M 4.13B 1.61B 20.22B 1.54B 1.51B 65.01B P/E 2026 *
-2.91x
P/E 2027 * -2.91x
Enterprise Value 120M 107M 99.72M 90.75M 171M 11.56B 172M 1.2B 469M 5.9B 450M 441M 18.96B EV / Sales 2026 *
-
EV / Sales 2027 * 7.83x
Free-Float
86.63%
Yield 2026 *
-
Yield 2027 * -
09-15 Atea Pharmaceuticals, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 12:20 PM
08-13 Morgan Stanley Adjusts PT on Atea Pharmaceuticals to $7 From $6, Maintains Equalweight Rating MT
08-12 Atea Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 12, 2026
08-12 Atea Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-28 Atea Pharmaceuticals Reports Positive Topline Results From C-BEYOND Phase 3 Trial Evaluating Bemnifosbuvir/Ruzasvir For Hepatitis C Virus CI
07-28 Atea Pharmaceuticals Says Combination Drug Meets Endpoints in Phase 3 Hepatitis C Trial MT
07-14 Atea Pharmaceuticals Initiates First-In-Human Phase 1 Clinical Trial Of AT-587 For The Treatment Of Hepatitis E Virus CI
07-14 Atea Pharmaceuticals Begins Phase 1 Clinical Trial of Potential Hepatitis E Treatment MT
06-25 Atea Pharmaceuticals Completes Enrollment in Phase 3 Hepatitis C Virus Trial Outside North America MT
06-25 Atea Pharmaceuticals, Inc. Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment Of Hepatitis C Virus CI
05-27 Atea Pharmaceuticals presents new drug-drug interaction results supporting potential best-in-class profile of the regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus at EASL Congress 2026 RE
05-27 Atea Pharmaceuticals Presents New Drug-Drug Interaction Results and Demonstrates High in Vitro Antiviral Potency and in Vivo Efficacy for At-587 CI
05-13 Atea Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 12, 2026
1 week-1.35%
Current month-1.54%
1 month-12.01%
3 months+3.01%
6 months-10.94%
Current year+43.70%
1 week 4.93
Extreme 4.93
5.29
1 month 4.93
Extreme 4.93
5.85
Current year 3.28
Extreme 3.285
6.45
1 year 2.87
Extreme 2.87
6.45
3 years 2.46
Extreme 2.455
6.45
5 years 2.46
Extreme 2.455
43.23
10 years 2.46
Extreme 2.455
94.17
Manager TitleAgeSince
Chief Executive Officer 70 2012-11-30
Director of Finance/CFO 63 2020-09-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 2012-11-30
Director/Board Member 61 2020-07-31
Director/Board Member 76 2019-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
5/18/26 Buy

Director

6,100 0.0077%
3/11/26 Exercice

Chief Financial Officer

120,000 0.1536%
1/31/26 Exercice

Executive/Senior Manager

215,256 0.2755%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-1.35%+76.90%+70.43% 411M
+4.16%+3.42%+49.37%+94.17% 74.31B
+1.70%-2.64%+21.51%+76.65% 56.95B
+2.19%+0.34%+5.17%+36.60% 48.3B
+0.50%+2.94%+344.62%+722.17% 44.51B
+3.05%-1.80%+28.78%+34.51% 43.8B
+1.00%-1.46%+5.17%+111.90% 41.12B
-0.54%+2.41%+9.31%+58.85% 31.07B
+4.51%+8.22%+37.86%+32.49% 28.97B
+0.76%-1.45%-7.44%-11.12% 24.53B
Average +1.73%-0.27%+57.12%+122.67% 39.4B
Weighted average by Cap. +2.13%-0.46%+58.86%+136.85%

Financials

2026 *2027 *
Net sales - 30M 26.76M 24.93M 22.69M 42.73M 2.89B 43.05M 301M 117M 1.47B 113M 110M 4.74B
Net income -146M -130M -121M -110M -208M -14.06B -209M -1.47B -570M -7.18B -548M -536M -23.07B -147M -131M -122M -111M -209M -14.16B -211M -1.48B -574M -7.23B -552M -540M -23.23B
Net Debt -291M -260M -242M -220M -415M -28.07B -418M -2.93B -1.14B -14.33B -1.09B -1.07B -46.05B -176M -157M -147M -133M -251M -17B -253M -1.77B -690M -8.67B -663M -648M -27.88B
Logo Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Its product candidate pipeline includes the regimen of bemnifosbuvir and ruzasvir which has the potential to improve the current standard of care (SOC) for the treatment of patients with hepatitis C virus (HCV) infection and AT-587 which has the potential to be the first direct-acting antiviral (DAA) for the treatment of patients, particularly immunocompromised patients, with chronic hepatitis E virus (HEV) infection. The global HCV Phase III program it is conducting consists of two randomized, open-label studies: C-BEYOND which has clinical trial sites in the United States and Canada, and C-FORWARD which has clinical trial sites in countries outside of North America. AT-587 has demonstrated potent nanomolar antiviral activity against HEV in vitro.
Employees
55
Date Price Change Volume
26-10-05 US$5.130 0.00% 293,607
26-10-02 US$5.130 +0.59% 253,264
26-10-01 US$5.100 -2.11% 408,661
26-09-30 US$5.210 +0.58% 296,281
26-09-29 US$5.180 -0.38% 298,348
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.130USD
Average target price
9.417USD
Spread / Average Target
+83.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVIR Stock